A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study

被引：0
|
作者：
Gao, Xin
Smith, Matthew Raymond
Scher, Howard I.
Verholen, Frank
Adorjan, Patrick
Dissanayake, Manjari
Laccetti, Andrew Leonard
机构：
[1] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Bayer Consumer Care AG, Basel, Switzerland
[5] Bayer Healthcare Pharmaceut Inc, Whippany, NJ 07981 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5111
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR).
    Laccetti, Andrew Leonard
    Smith, Matthew Raymond
    Scher, Howard I.
    Verholen, Frank
    Adorjan, Patrick
    Dissanayake, Manjari
    Gao, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS243 - TPS243
  • [2] Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
    Tombal, Bertrand
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Van Poppel, Hendrik
    Heidenreich, Axel
    Iversen, Peter
    Braeckman, Johan
    Heracek, Jiri
    Baskin-Bey, Edwina
    Ouatas, Taoufi K.
    Perabo, Frank
    De Phung
    Hirmand, Mohammad
    Smith, Matthew R.
    LANCET ONCOLOGY, 2014, 15 (06): : 592 - 600
  • [3] Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer
    Tombal, Bertrand
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Heidenreich, Axel
    Iversen, Peter
    Baskin-Bey, Edwina S.
    Perabo, Frank
    Phung, De
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [4] A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532).
    Tombal, Bertrand F.
    Gomez-Veiga, Francisco
    Gomez-Ferrer, Alvaro
    Lopez-Campos, Fernando
    Ost, Piet
    Roumeguere, Thierry Andre
    Herrera-Imbroda, Bernardo
    D'Hondt, Lionel A.
    Quivrin, Magali
    Gontero, Paolo
    Villa, Salvador
    Khaled, Hussein Mustafa
    Fournier, Beatrice
    Krzystyniak, Joanna
    Pretzenbacher, Yassin
    Erkol, Hazal
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [5] Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients
    Tombal, Bertrand
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Van Poppel, Hendrik
    Heidenreich, Axel
    Iversen, Peter
    Braeckman, Johan
    Heracek, Jiri
    Baskin-Bey, Edwina
    Ouatas, Taoufik
    Perabo, Frank
    Phung, De
    Smith, Matthew R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [6] Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients.
    Tombal, Bertrand F.
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Van Poppet, Hendrik
    Heidenreich, Axel
    Iversen, Peter
    Braeckman, Johan
    Heracek, Jiri
    Baskin-Bey, Edwina
    Ouatas, Taoufik
    Perabo, Frank
    De Phung
    Hirmand, Mohammad
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)
    Tombal, Bertrand F.
    Gomez-Veiga, Francisco
    Gomez-Ferrer, Alvaro
    Lopez-Campos, Fernando
    Ost, Piet
    Roumeguere, Thierry Andre
    Herrera-Imbroda, Bernardo
    D'Hondt, Lionel A.
    Quivrin, Magali
    Gontero, Paolo
    Villa, Salvador
    Khaled, Hussein
    Fournier, Beatrice
    Musoro, Jammbe
    Krzystyniak, Joanna
    Pretzenbacher, Yassin
    Loriot, Yohann
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (05): : 1051 - 1060
  • [8] A randomized, open-label, phase 2 study of enzalutamide as neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer
    Montgomery, B.
    Joshua, A.
    Gleave, M.
    Fleshner, N.
    Bubley, G.
    True, L.
    Tretiakova, M.
    Wu, K.
    Novotny, W.
    Peterson, A.
    Amelsberg, A.
    Taplin, M. E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S473 - S473
  • [9] A phase II, open-label, single-arm, efficacy, and safety study of MDV3100 in patients with hormone-naive prostate cancer
    Baskin-Bey, E. S.
    Holtkamp, G. M.
    Smith, M. R.
    Ouatas, T.
    Phung, D.
    Tombal, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [10] Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naive Prostate Cancer: 1-and 2-Year Open-label Follow-up Results
    Tombal, Bertrand
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Van Poppel, Hendrik
    Heidenreich, Axel
    Iversen, Peter
    Braeckman, Johan
    Heracek, Jiri
    Baskin-Bey, Edwina
    Ouatas, Taoufik
    Perabo, Frank
    Phung, De
    Baron, Benoit
    Hirmand, Mohammad
    Smith, Matthew R.
    EUROPEAN UROLOGY, 2015, 68 (05) : 787 - 794
12345